Regeneron Pharmaceuticals Inc
NASDAQ: REGN
$744.50
+$1.15 (+0.2%)
Closing Price on November 21, 2024
REGN Articles
Wednesday's top analyst upgrades and downgrades included AbbVie, Albertsons, DuPont, Exxon Mobil, Home Depot, KB Home, Mastercard, Palantir and Twitter.
Published:
In a move that investors looking for more defensive ideas should applaud, the analysts at Goldman Sachs have added Bristol-Myers Squibb to the Americas Conviction List. Plus, here are four additional...
Published:
The November 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
The November 13 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published:
Regeneron Pharma reported its third-quarter financial results before the markets opened on Thursday.
Published:
24/7 Wall St. has put together a preview of the most prominent earnings reports this week, including General Motors, T-Mobile and Uber.
Published:
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Published:
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Here are 13 other companies that should seriously entertain splitting their stocks. Splits are of course a gimmick, but the stock market usually rewards companies for splitting their stocks.
Published:
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic selling...
Published:
The September 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
Tuesday's top analyst upgrades and downgrades included Alexion Pharmaceuticals, Bill.com, Boeing, Costco, Dicks Sporting Goods, Generac, Proofpoint, Regeneron Pharmaceuticals and Shopify.
Published:
Many health care products become much more popular because of endorsements and advertising efforts. It is a longstanding practice that has come under fire by both political parties in the United...
Published:
Monday's top analyst upgrades and downgrades included American Express, AT&T, CRISPR Therapeutics, DocuSign, ONEOK, Regeneron Pharmaceuticals, Shopify and Tesla.
Published: